Publications by authors named "T Blaschke"
Article Synopsis
- * The analysis was done on a group of 505 patients, with a detailed subset of 198, all from a database of individuals with NMOSD in North America to identify factors affecting disability over time.
- * Key findings revealed that prior relapses were linked to worse mobility, vision, and self-care, with additional insights showing that certain demographics, like race and disease subtype, impacted disability, highlighting the need for specialized assessments for NMOSD to better manage and understand
The reviews in Volume 64 of the cover diverse topics. A common theme in many of the reviews is the interindividual variability in the clinical response to drugs. Highlighted areas include emerging developments in pharmacogenomics that can predict the personal risk for drug inefficacy and/or adverse drug reactions.
View Article and Find Full Text PDFUsing generative deep learning models and reinforcement learning together can effectively generate new molecules with desired properties. By employing a multi-objective scoring function, thousands of high-scoring molecules can be generated, making this approach useful for drug discovery and material science. However, the application of these methods can be hindered by computationally expensive or time-consuming scoring procedures, particularly when a large number of function calls are required as feedback in the reinforcement learning optimization.
View Article and Find Full Text PDFObjective: Neuromyelitis optica spectrum disorders (NMOSD) represent rare autoimmune diseases of the central nervous system largely targeting optic nerve(s) and spinal cord. The present analysis used real-world data to identify clinical and epidemiological correlates of treatment change in patients with NMOSD.
Methods: CIRCLES is a longitudinal, observational study of NMOSD conducted at 15 centers across North America.
Background: Timely, accurate adherence data may support oral pre-exposure prophylaxis (PrEP) success and inform prophylaxis choice. We evaluated a Food and Drug Administration (FDA)-approved digital health feedback system (DHFS) with ingestible-sensor-enabled (IS) tenofovir-disoproxil-fumarate plus emtricitabine (Truvada®) in persons starting oral PrEP.
Methods: Human immunodeficiency virus (HIV)-negative adults were prescribed IS-Truvada® with DHFS for 12 weeks to observe medication taking behavior.